Dynamics of Lipid Profile in Patients With Alopecia Areata Treated With Ritlecitinib: A Descriptive, Retrospective,...

Area of Science:

• Dermatology
• Pharmacology
• Metabolic Medicine

Background:

• Alopecia areata (AA) is an autoimmune condition with limited treatment options.
• Ritlecitinib is an emerging therapy for AA, but its impact on lipid metabolism requires further investigation.
• Real-world data on ritlecitinib's effects on lipid profiles in AA patients are scarce.

Purpose of the Study:

• To evaluate the effects of ritlecitinib on lipid metabolism in patients with AA.
• To assess changes in lipid profiles and atherogenic index of plasma (AIP) during ritlecitinib therapy.
• To compare lipid profile changes between patients with normal and abnormal baseline lipid levels.

Main Methods:

• A retrospective cohort study involving 55 AA patients treated with ritlecitinib for at least 24 weeks.
• Fasting serum lipid parameters and AIP were measured at baseline, 12, and 24 weeks.
• Comparative analyses were performed based on baseline lipid profiles.

Main Results:

• Ritlecitinib therapy maintained stable conventional lipid parameters over 24 weeks.
• A significant reduction in AIP was observed at 12 weeks (P < .05).
• Patients with baseline dyslipidemia showed improvements in atherogenic lipid fractions.

Conclusions:

• Ritlecitinib demonstrates a favorable lipid safety profile in AA patients.
• The study suggests potential metabolic benefits of ritlecitinib, particularly for patients with preexisting dyslipidemia.
• Further research in diverse populations is warranted due to the single-center, Chinese-limited cohort.